Jan. 9 at 8:20 AM
$ASRT
By Nick Paul Taylor Oct 31, 2022 9:55am
Aquestive offloads film formulation seizure drug to Assertio, securing cash for epinephrine R&D
partnership, collaboration, legal document Assertio is buying Sympazan as part of its push to acquire
$40 million in gross profit by 2024. Specialty pharma company Assertio Holdings has expanded its portfolio through a deal with Aquestive Therapeutics, paying
$9 million upfront for exclusive rights to the Sympazan oral film formulation.
Sympazan is a formulation of clobazam, a benzodiazepine class medication, that is authorized to treat seizures associated with Lennox-Gastaut syndrome. The product uses Aquestive’s PharmFilm to provide an alternative to pill and liquid formulations of clobazam. Patients put the film on the tongue, where it dissolves without the use of water.
Aquestive generated revenues of
$9.5 million from Sympazan over the past 12 months but has decided it is best served by cashing in.
